Full Text View
Tabular View
No Study Results Posted
Related Studies
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
This study has been terminated.
Study NCT00113048   Information provided by Sanofi

First Received on June 3, 2005.   Last Updated on February 4, 2014   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Sponsors listed in this trial